Jun 18 |
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
|
Jun 17 |
Assembly Biosciences closes $12.6M in equity financings
|
Jun 17 |
Assembly Biosciences Announces $12.6 Million in Equity Financings
|
Jun 10 |
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
|
Jun 5 |
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
|
May 22 |
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
|
May 16 |
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
|
May 9 |
Assembly Biosciences GAAP EPS of -$1.66 beats by $1.57, revenue of $5.79M
|
May 8 |
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
|
Apr 9 |
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
|